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Abstract Phosphorylation of CPI-17 and PHI-1 by the
MYPT1-associated kinase (M110 kinase) was investigated.
M110 kinase is a recently identified serine/threonine kinase with
a catalytic domain that is homologous to that of ZIP kinase
(ZIPK. GST-rN-ZIPK, a constitutively active GST fusion
fragment, phosphorylates CPI-17 (but not PHI-1) to a
stoichiometry of 1.7 mol/mol. Phosphoamino acid analysis
revealed phosphorylation of both Ser and Thr residues.
Phosphorylation sites in CPI-17 were identified as Thr 38 and
Ser 12 using Edman sequencing with 32P release and a point
mutant of Thr 38. ß 2001 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Contractile activity in smooth muscle is linked to transients
in [Ca2]i that activate the phosphorylation of the 20 kDa
myosin light chain (MLC20) [1,2]. The level of phosphorylat-
ed MLC20 is determined by a balance of the activity of two
counteracting enzymes: a Ca2-calmodulin-dependent myosin
light chain kinase and a myosin light chain phosphatase
(SMPP-1M) [3,4]. However, at ¢xed Ca2 levels contraction
also can be induced by agonist stimulation or by activation of
G-proteins [5,6]. This leads to so-called Ca2 sensitization [6^
8] and is correlated with an inhibition of SMPP-1M activity
[5,9]. The inhibition of SMPP-1M following agonist stimula-
tion was proposed to occur via the small GTPase RhoA and
one of its downstream targets, Rho kinase [9,10].
Protein phosphatase 1 (PP-1) is one of the major Ser/Thr
protein phosphatases in eukaryotic cells, and di¡erent forms
of PP-1 are composed of a catalytic subunit and di¡erent
regulatory subunits that target the phosphatase to speci¢c
locations and particular substrates [11,12]. The smooth muscle
myosin targeted phosphatase, SMPP-1M, is composed of
three subunits : the 37 kDa catalytic subunit of PP-1 (PP-
1CN), a 110^130 kDa regulatory myosin phosphatase targeting
subunit (MYPT1) and a 20 kDa subunit of undetermined
function [13]. SMPP-1M inhibition occurs in response to
phosphorylation of the MYPT1 subunit by Rho kinase [10],
or an endogenously associated MYPT1 kinase [14]. A recent
report presented the previously unidenti¢ed SMPP-1M-asso-
ciated kinase [15] as a close relative to ZIP kinase (ZIPK).
This newly identi¢ed M110 kinase was shown to associate
with MYPT1 and phosphorylate an inhibitory site on
MYPT1. It was suggested that the M110 kinase could act
downstream of RhoA and Rho kinase in the Ca2 sensitiza-
tion mechanism in the smooth muscle and that M110 kinase
may be the terminal member of a Ca2 sensitizing kinase
cascade.
The myosin phosphatase activity of SMPP-1M also can be
regulated by a smooth muscle speci¢c 17 kDa inhibitory phos-
phoprotein, CPI-17 [16]. Phosphorylation of CPI-17 at Thr 38
by PKC [17] or an unidenti¢ed endogenous kinase [16] en-
hanced the inhibitory potency toward SMPP-1M by about
103. Agonist-induced CPI-17 phosphorylation was demon-
strated in intact smooth muscle and about half this response
was due to a kinase sensitive to Y-27632, i.e. Rho kinase and/
or PKN [18]. Subsequently, CPI-17 was shown to be an in
vitro substrate of both Rho kinase [19] and PKN [20]. Here
we examined whether CPI-17 is a substrate for the recently
identi¢ed M110 kinase.
2. Materials and methods
2.1. Materials
Constitutively active recombinant GST-ZIPK encoding the N-ter-
minal1ÿ320 portion of ZIPK (GST-rN-ZIPK) was produced from
I.M.A.G.E. cDNA clone AI660136 (Genome Systems Inc., MO,
USA) [15]. The cDNA clone was in-frame inserted into vector
pGEX-4T-1 (Amersham Pharmacia Biotech) in order to express the
glutathione S-transferase (GST) fusion protein. Escherichia coli cells
were cultured in LB broth, 50 Wg/ml ampicillin, overnight at 37‡C.
Cells were induced with 100 WM isopropyl-L-D-thiogalactopyranoside,
and GST-rN-ZIPK was isolated using glutathione-Sepharose 4B
beads according to the manufacturer’s instructions. HtCPI-17,
HtCPI-17T38A, and HtPHI-1 recombinant fusion proteins were pre-
pared and puri¢ed as described previously [21]. [Q-32P]ATP was ob-
tained from ICN. All other chemicals were of reagent grade.
2.2. Protein phosphorylation
Phosphorylation of HtCPI-17 and HtCPI-17T38A proteins (50 Wg)
by GST-rN-ZIPK (5 Wg) was carried out at 23‡C in 25 mM HEPES,
pH 7.2, 1 mM MgCl2, 0.1 mM dithiothreitol (DTT) with 0.2 mM
[Q-32P]ATP. The reactions were initiated by addition of [Q-32P]ATP
and the stoichiometry of CPI-17 phosphorylation was measured by
terminating the kinase reactions with 25% trichloroacetic acid (TCA)
after pre-determined time intervals. The reactions were centrifuged for
5 min at 20 000Ug ; the protein precipitate was washed three times
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with 25% TCA, and the radioactivity incorporated into the precipi-
tated proteins was assessed by Cerenkov counting.
2.3. Phosphorylation site analysis
Recombinant CPI-17 proteins were phosphorylated for 3 h at 25‡C
in a 100 Wl volume containing 20 Wg recombinant CPI-17, 25 mM
HEPES, pH 7.2, 5 mM MgCl2, 0.1 mM DTT, 0.5 mM [Q-32P]ATP
(250 cpm/nmol) and 2 Wg GST-rN-ZIPK. 32P-labeled CPI-17 samples
from in vitro phosphorylation reactions were incubated with 0.5 Wg of
endoproteinase Lys-C at 37‡C for 15 h. The digests were acidi¢ed by
the addition of tri£uoroacetic acid (TFA). Peptides were puri¢ed away
from contaminating [32P]ATP by repetitively passing the sample over
a C18 Zip-Tip (Millipore) followed by repetitive washes in 0.1% TFA.
Peptides were eluted in a 10 Wl of 80% acetonitrile/0.1% TFA. Pep-
tides were immobilized to Immobilon membrane (Millipore) following
the manufacturer’s instructions. The membrane was placed into a 494
Procise sequencing cartridge (Applied Biosystems). Phosphorylated
residues within phosphopeptides were located by determining the
cycles in which 32P was released when samples were subjected to
sequential Edman degradation under conditions that optimized recov-
ery of 32P [22]. The cleaved radioactive protein (CRP) analysis pro-
gram was used to assign a phosphorylation site to the 32P released in a
speci¢c cycle. The CRP analysis program is available at http://
wrpx1.bioch.virginia.edu/crap/.
2.4. Other procedures
Phosphoamino acid analysis of TCA-precipitated CPI-17 was per-
formed as described previously [23]. SDS^PAGE was carried out with
the discontinuous bu¡er system of Laemmli [24]. Protein concentra-
tions were determined using the Bradford (Bio-Rad) procedure with
bovine serum albumin as a standard.
3. Results
3.1. Phosphorylation of CPI-17 by GST-rN-ZIPK
The phosphorylation of recombinant HtCPI-17 and re-
combinant HtPHI-1 by GST-rN-ZIPK was examined. As
shown in Fig. 1A, HtCPI-17 was a good substrate for GST-
rN-ZIPK. PHI-1, a widely expressed analog protein of CPI-17
with nearly identical sequence at the primary site of phosphor-
ylation, was not phosphorylated to any extent by GST-rN-
ZIPK. Mutation of the known critical phosphorylation site by
substitution of Ala for Thr 38 (HtCPI-17T38A) in CPI-17 re-
duced 32P incorporation. Mutation of Thr 57 to Ala in PHI-1
had no e¡ect on phosphorylation. The time course and stoi-
chiometry of phosphorylation by GST-rN-ZIPK for HtCPI-
17 were examined (Fig. 2). HtCPI-17 was phosphorylated to
1.7 mol phosphate/mol of protein while HtCPI-17T38A was
phosphorylated to 0.3 mol of phosphate/mol of protein over
a 160 min incubation. Phosphorylation of Thr 38 makes CPI-
17 a high potency inhibitor of the myosin phosphatase [16,17],
and our results indicate that recombinant GST-rN-ZIPK can
e⁄ciently and speci¢cally phosphorylate Thr 38 in CPI-17 in
vitro.
3.2. Identi¢cation of Thr 38 and Ser 12 as phosphorylation sites
by Edman sequencing
Phosphoamino acid analysis revealed phosphorylation of
both Ser and Thr residues in HtCPI-17 (Fig. 1B). When
HtCPI-17T38A phosphorylation was analyzed, there was nearly
complete reduction of phospho-Thr while phospho-Ser was
still present. Phosphorylation of HtCPI-17 at Thr 38 was con-
¢rmed by Edman sequencing with 32P release (Fig. 3A) and
the CRP analysis program (Fig. 3B). Endoproteinase Lys-C
digestion of phosphorylated HtCPI-17 followed by solid
phase Edman sequencing indicated that the incorporated 32P
was released in the fourth and sixth cycles. CRP analysis of
HtCPI-17 revealed that the only residue that could yield the
release of 32P in the fourth cycle was Ser 12. Both Thr 38 and
Thr 104 could yield the release of 32P in the sixth cycle. How-
ever, when HtCPI-17T38A was digested with endoproteinase
Fig. 1. A: Phosphorylation of CPI-17 and PHI-1 by GST-rN-ZIPK.
HtCPI-17 (lane 1), HtCPI-17T38A (lane 2), HtPHI-1 (lane 3), and
HtPHI-1T57A (lane 4) were phosphorylated with GST-rN-ZIPK for
15 min. GST-rN-ZIPK was incubated alone as a control (lane 5).
Each sample (20 Wg) was separated by SDS^PAGE and subjected to
autoradiography. B: Phosphoamino acid analysis of HtCPI-17 and
HtCPI-17T38A phosphorylated by GST-rN-ZIPK.
Fig. 2. Stoichiometry of phosphorylation of CPI-17 by GST-rN-
ZIPK. Wild-type HtCPI-17 (7) and HtCPI-17T38A (a) were phos-
phorylated by GST-rN-ZIPK for the indicated time under the con-
ditions described. GST-rN-ZIPK (E) was also incubated alone as a
control.
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Lys-C and subjected to Edman sequencing, 32P was only de-
tected in the fourth cycle. CRP analysis of HtCPI-17T38A in-
dicated the phosphorylation of only Ser 12. In addition, CRP
analysis and 32P cycle data of endoproteinase Lys-C-derived
peptides that were further digested with endoproteinase Arg-C
produced results (data not shown) which were consistent with
phosphorylation of Thr 38 and Ser 12 in HtCPI-17 by GST-
rN-ZIPK. The HtCPI-17T38A protein was a poorer substrate
for phosphorylation of Ser 12. The amount of 32P incorpora-
tion into Ser 12 in HtCPI-17T38A was only 25% of that recov-
ered from the wild-type HtCPI-17. This observation may in-
dicate an ordered phosphorylation process in which prior
phosphorylation of Thr 38 enhances the phosphorylation of
Ser 12.
4. Discussion
CPI-17 was identi¢ed as a 17 kDa phosphorylation-depen-
dent inhibitory protein of myosin light chain phosphatase [16].
CPI-17 expression was found to be speci¢c to smooth muscle
tissues such as aorta and bladder[17], and the protein was
implicated in PKC-mediated Ca2 sensitization of smooth
muscle contraction [16,25]. Studies have shown that agonist
stimulation of intact and permeabilized smooth muscle results
in CPI-17 phosphorylation of Thr 38, a site that enhances
inhibitory potency 1000-fold [18]. Presumably, this phosphor-
ylation occurs via a G-coupled mechanism via RhoA and its
downstream partner Rho kinase, although other kinases in-
cluding PKN and PKC may be involved. When smooth
muscle was stimulated by the addition of agonists in the pres-
ence of PKC and Rho kinase inhibitors, the e¡ect varied with
the agonist used; thus it was suggested that some combination
of signal transduction pathways is in operation to contribute
to the SMPP-1M inhibition that is witnessed during Ca2
sensitization. As well, Rho kinase can phosphorylate the
MYPT1 subunit of myosin phosphatase in vitro and inhibit
SMPP-1M activity [10].
M110 kinase, the previously unidenti¢ed SMPP-1M-associ-
ated kinase, is a recently identi¢ed serine/threonine kinase [15]
with a catalytic domain in its N-terminal region that is ho-
mologous to that of ZIPK. Associated with SMPP-1M, M110
kinase can phosphorylate the inhibitory site of MYPT1 in
intact smooth muscle and, as demonstrated in this study,
the potentiating site on CPI-17. Many reports have docu-
mented the important role played by RhoA in Ca2 sensitiza-
tion (review [3]) and its downstream partner Rho kinase has
also been implicated [26,27]. One potential problem with Rho
kinase being the ¢nal link to MYPT1 and CPI-17 is the local-
ization of the active enzyme. It has been demonstrated that
Ca2 sensitization of smooth muscle involves translocation of
RhoA to the membrane [28] where it presumably targets Rho
kinase. The activated Rho kinase at the membrane and its
substrates on myo¢brils might be linked by M110 kinase. In
this hypothesis the M110 kinase would act as a shuttle be-
tween Rho kinase and the contractile apparatus.
GST-rN-ZIPK is a constitutively active, recombinant N-
terminal fragment of ZIPK that has an identical sequence to
the smooth muscle M110 kinase (M. Borman, unpublished
data). Because the catalytic characteristics of GST-rN-ZIPK
are essentially the same as the puri¢ed native M110 kinase
[15], we used GST-rN-ZIPK to analyze the phosphorylation
of CPI-17 by M110 kinase. Using a point mutant of CPI-17
and the CRP analysis program with data obtained from the
sequential Edman degradation under conditions that opti-
mized recovery of 32P, we were able to identify Thr 38 as
the primary and stoichiometric phosphorylation site. This is
the previously identi¢ed inhibitory site that is phosphorylated
by PKC, PKN, Rho kinase and an unidenti¢ed endogenous
kinase.
We have identi¢ed Ser 12 as a novel site of phosphorylation
in CPI-17. It has been shown that native CPI-17 is phosphor-
ylated by PKN to a stoichiometry approximating 1.5 mol/mol
[20] and recombinant CPI-17 is phosphorylated by both PKN
[20] and Rho kinase [19] to a stoichiometry greater than 1.5
mol/mol. These previous results suggested the presence of an
additional site of phosphorylation on CPI-17. It is possible,
but yet unproven, that the secondary site of phosphorylation
by all of these kinases is Ser 12. It is interesting that the
second site phosphorylation tends to be less than stoichiomet-
ric, and phosphorylation of T38A versions of CPI-17 is much
less e⁄cient. Thus, it seems that CPI-17 undergoes ordered or
hierarchical phosphorylation at Thr 38 followed by Ser 12.
This observation is consistent with a conformational change
Fig. 3. Phosphorylation site analysis of CPI-17. HtCPI-17 and
HtCPI-17T38A were phosphorylated by GST-rN-ZIPK. Samples were
treated with endoproteinase Lys-C and applied to an Edman se-
quencer. Radioactivity was collected after each cycle (A) and com-
pared with theoretical results obtained from the CRP analysis pro-
gram (B). The CRP analysis data include: the Edman sequence
cycle number (Bin #) ; any Ser, Thr or Tyr residues present in the
protein (Potential Phosphorylation Sites) ; the number of phosphory-
latable residues present in a particular Bin# (# in bin) ; and the per-
centage of phosphorylatable residues included within the number of
Edman sequencing cycles (Coverage).
FEBS 24713 26-3-01
J.A. MacDonald et al./FEBS Letters 493 (2001) 91^94 93
upon phosphorylation of Thr 38 that exposes Ser 12 for re-
action with kinases.
PHI-1 is a phosphatase holoenzyme inhibitor protein with
sequence similarity to CPI-17 and is phosphorylated in both
Thr and Ser residues [29]. Phosphorylation of PHI-1 and en-
hancement of inhibitory potency by PKC have been reported
[29] though it is not yet known if the protein is also a sub-
strate for Rho kinase. Interestingly, GST-rN-ZIPK had no
reactivity with PHI-1 as a substrate even though the sequence
at the phosphorylation site of CPI-17 is RVTVKY compared
to KVTVKY for PHI-1. Whether M110 kinase is a smooth
muscle speci¢c isozyme remains to be determined; however, it
is interesting that the GST-rN-ZIPK speci¢cally phosphory-
lates a PP-1 inhibitory protein found exclusively in smooth
muscle.
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